​

AnaptysBio (ANAB) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

ANAB Stock Forecast

AnaptysBio (ANAB) stock forecast, based on 11 Wall Street analysts, predicts a 12-month average price target of $49.83, with a high of $90.00 and a low of $19.00. This represents a 186.05% increase from the last price of $17.42.

$10 $26 $42 $58 $74 $90 High: $90 Avg: $49.83 Low: $19 Last Closed Price: $17.42

ANAB Stock Rating

AnaptysBio stock's rating consensus is Buy, based on 11 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 6 Buy (54.55%), 5 Hold (45.45%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 11 0 5 6 Strong Sell Sell Hold Buy Strong Buy

ANAB Forecast vs Benchmarks

TypeNameUpside
StockAnaptysBio186.05%
SectorHealthcare Stocks 25.20%
IndustryBiotech Stocks 63.35%

Price Target Trends

1M3M12M
# Anlaysts-38
Avg Price Target-$38.67$49.75
Last Closing Price$17.42$17.42$17.42
Upside/Downside-121.99%185.59%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 25263--11
Dec, 24374--14
Nov, 24472--13
Oct, 24572--14
Sep, 24572--14
Latest Price Target by Analysts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 11, 2024Emily BodnarH.C. Wainwright$19.00$15.5122.50%9.07%
Nov 06, 2024Emily BodnarH.C. Wainwright$52.00$19.38168.32%198.51%
Nov 06, 2024David RisingerLeerink Partners$45.00$19.38132.20%158.32%
Oct 21, 2024Yatin SunejaGuggenheim$90.00$34.98157.29%416.65%
Oct 15, 2024Yasmeen RahimiPiper Sandler$80.00$34.74130.28%359.24%
Oct 03, 2024David RisingerNew Street$35.00$35.22-0.62%100.92%
Aug 15, 2024Joon LeeTruist Financial$30.00$34.65-13.42%72.22%
Apr 16, 2024David RisingerLeerink Partners$47.00$21.27120.97%169.80%
Nov 18, 2022J.P. Morgan$32.00$29.169.74%83.70%
Latest Upgrade/Downgrade by Analysts
DateCompanyPrevious RatingNew RatingRating Change
Dec 11, 2024H.C. WainwrightBuyNeutraldowngrade
Dec 02, 2024BTIGNeutraldowngrade
Oct 30, 2024H.C. WainwrightBuyBuyhold
Oct 21, 2024WedbushBuyBuyhold
Oct 21, 2024GuggenheimBuyBuyhold
Oct 15, 2024Piper SandlerOverweightOverweighthold
Oct 03, 2024Leerink PartnersOutperformOutperformhold
Sep 26, 2024WedbushBuyBuyhold
Aug 06, 2024WedbushBuyBuyhold
Aug 06, 2024Cowen & Co.BuyBuyhold

Financial Forecast

EPS Forecast

$-15 $-11 $-7 $-3 $1 $5 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.73$-2.08$-4.57$-6.08-----
Avg Forecast$0.04$-1.83$-4.53$-6.07$-6.08$-5.36$-5.35$-5.76$-5.69
High Forecast$0.01$-2.67$-8.20$-6.32$-6.22$-7.28$-8.61$-10.23$-13.73
Low Forecast$0.06$-0.60$-1.76$-5.95$-5.70$-3.66$-2.69$-1.92$0.16
Surprise %-1925.00%13.66%0.88%0.16%-----

Revenue Forecast

$0 $40M $80M $120M $160M $200M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$75.00M$63.17M$10.29M$17.16M-----
Avg Forecast$95.00M$63.17M$9.05M$11.94M$55.92M$35.45M$45.32M$60.90M$79.97M
High Forecast$45.91M$30.52M$4.80M$6.09M$45.09M$7.39M$44.57M$12.70M$16.68M
Low Forecast$128.49M$85.43M$14.70M$14.69M$73.19M$73.97M$46.07M$127.08M$166.87M
Surprise %-21.05%0.01%13.64%43.67%-----

Net Income Forecast

$-400M $-310M $-220M $-130M $-40M $50M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-19.92M$-57.19M$-128.72M$-163.62M-----
Avg Forecast$-12.30M$-49.34M$-26.58M$-163.62M$-165.66M$-184.77M$-204.22M$-233.66M$-153.20M
High Forecast$-30.06M$-71.95M$-46.20M$-284.39M$-167.59M$-196.12M$-231.86M$-275.43M$-369.63M
Low Forecast$5.46M$-16.19M$-6.96M$-42.85M$-153.58M$-98.59M$-72.41M$-51.69M$4.42M
Surprise %61.95%15.92%384.26%------

ANAB Forecast FAQ

Is AnaptysBio stock a buy?

AnaptysBio stock has a consensus rating of Buy, based on 11 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 6 Buy, 5 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that AnaptysBio is a favorable investment for most analysts.

What is AnaptysBio's price target?

AnaptysBio's price target, set by 11 Wall Street analysts, averages $49.83 over the next 12 months. The price target range spans from $19 at the low end to $90 at the high end, suggesting a potential 186.05% change from the previous close price of $17.42.

How does AnaptysBio stock forecast compare to the average forecast of its sector, industry, and investment themes?

AnaptysBio stock forecast shows a 186.05% upside, outperforming the average forecast for the healthcare stocks sector (25.20%) and outperforming the biotech stocks industry (63.35%).

What is the breakdown of analyst ratings for AnaptysBio over the past three months?

  • January 2025: 18.18% Strong Buy, 54.55% Buy, 27.27% Hold, 0% Sell, 0% Strong Sell.
  • December 2024: 21.43% Strong Buy, 50.00% Buy, 28.57% Hold, 0% Sell, 0% Strong Sell.
  • November 2024: 30.77% Strong Buy, 53.85% Buy, 15.38% Hold, 0% Sell, 0% Strong Sell.

What is AnaptysBio’s EPS forecast?

AnaptysBio's average annual EPS forecast for its fiscal year ending in December is -6.08 for 2024, a 0% decrease from the reported $-6.08 in 2023. The prediction for 2025 is $-5.36, $-5.35 for 2026, $-5.76 for 2027, and $-5.69 for 2028.

What is AnaptysBio’s revenue forecast?

AnaptysBio's average annual revenue forecast for its fiscal year ending in December is $55.92M for 2024, a 225.91% increase from the reported $17.16M in 2023. The forecast for 2025 is $35.45M, $45.32M for 2026, $60.9M for 2027, and $79.97M for 2028.

What is AnaptysBio’s net income forecast?

For its fiscal year ending in December, AnaptysBio's average annual net income forecast is $-166M for 2024, reflecting an 1.25% increase from the reported $-164M in 2023. The projection for 2025 is $-185M, $-204M for 2026, $-234M for 2027, and $-153M for 2028.